With regard to the tumor stage, we found that RFS duration was significantly shorter in patients with PROK2-positive tumors than in those with PROK2-negative tumors among patients with stage II (p = 0.020; Figure 2B) and III CRC (p = 0.023; Figure 2C). This evidence concerns the gene PROK2 and colorectal carcinoma.